According to market research firm AIOCD, at least 50 Indian drug makers are jumping into the fray with around 100 generic versions of the popular anti-diabetes medication, leading to a likely price war.
Analysts expect prices to drop by 60% with the entry of generics, and intensify competition for vildagliptin and teneligliptin, two molecules of the same class that went off-patent in 2019 and 2015, respectively.
Januvia – which goes by the generic name sitagliptin – comes under the class of dipeptidyl peptidase (DPP4) inhibitors.
MSD also sells a fixed dose combination of sitagliptin and metformin under the brand name Janumet.
Sun Pharma also markets sitagliptin and a sitagliptin-metformin combination in India under licence from MSD.
The current market for sitagliptin and its combinations are around ₹1,000 crore, which is 10% of India’s oral anti-diabetes drug market.
At present, a 100mg tablet of Januvia costs around ₹45 MRP, while the 50mg one costs ₹37.80. Janumet 50/500 mg and 50/1000 mg costs ₹27, and Janumet extended-release costs ₹41.